Wells Fargo
QTTB icon

Wells Fargo’s Q32 Bio QTTB Stock Holding History

Wells Fargo’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-84
Closed -$539 – 7651
2026
Q1 		$539 Buy
+84
New +$399 ﹤0.01% 6391
2025
Q3 		– Sell
-139
Closed -$207 – 7458
2025
Q2 		$207 Sell
139
-3,519
-96% -$6K ﹤0.01% 6440
2025
Q1 		$6.04K Buy
3,658
+80
+2% +$215 ﹤0.01% 5995
2024
Q4 		$12.3K Buy
3,578
+799
+29% +$25.2K ﹤0.01% 5891
2024
Q3 		$124K Buy
2,779
+52
+2% +$1.91K ﹤0.01% 4889
2024
Q2 		$49K Buy
2,727
+2,648
+3,352% +$63.4K ﹤0.01% 5297
2024
Q1 		$1.35K Sell
79
-15
-16% -$207 ﹤0.01% 6090
2023
Q4 		$1.03K Hold
94
– – ﹤0.01% 6216
2023
Q3 		$1.97K Sell
94
-26
-22% -$530 ﹤0.01% 6095
2023
Q2 		$1.91K Hold
120
– – ﹤0.01% 6217
2023
Q1 		$2.22K Buy
120
+45
+60% +$1.12K ﹤0.01% 6208
2022
Q4 		$1.7K Sell
75
-39
-34% -$1.03K ﹤0.01% 6048
2022
Q3 		$3K Buy
114
+7
+7% +$285 ﹤0.01% 6093
2022
Q2 		$4K Sell
107
-3,365
-97% -$115K ﹤0.01% 6122
2022
Q1 		$190K Sell
3,472
-637
-16% -$39.6K ﹤0.01% 5009
2021
Q4 		$269K Buy
4,109
+1,188
+41% +$115K ﹤0.01% 5104
2021
Q3 		$413K Buy
2,921
+2,865
+5,116% +$365K ﹤0.01% 4767
2021
Q2 		$7K Sell
56
-374
-87% -$46.7K ﹤0.01% 6250
2021
Q1 		$73K Sell
430
-1,170
-73% -$246K ﹤0.01% 5632
2020
Q4 		$325K Buy
1,600
+672
+72% +$130K ﹤0.01% 4827
2020
Q3 		$178K Sell
928
-334
-26% -$74.8K ﹤0.01% 5014
2020
Q2 		$346K Buy
1,262
+370
+41% +$98.6K ﹤0.01% 4584
2020
Q1 		$250K Sell
892
-561
-39% -$172K ﹤0.01% 4537
2019
Q4 		$542K Buy
1,453
+512
+54% +$147K ﹤0.01% 4299
2019
Q3 		$307K Buy
941
+362
+63% +$123K ﹤0.01% 4712
2019
Q2 		$204K Buy
579
+164
+40% +$64.5K ﹤0.01% 4961
2019
Q1 		$207K Sell
415
-225
-35% -$101K ﹤0.01% 4805
2018
Q4 		$258K Buy
640
+297
+87% +$112K ﹤0.01% 4766
2018
Q3 		$141K Buy
343
+244
+246% +$82.9K ﹤0.01% 5196
2018
Q2 		$36K Buy
+99
New +$35.4K ﹤0.01% 5682

Other funds holding QTTB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wells Fargo's QTTB Position: Q2 2026 in Review

Wells Fargo sold out of Q32 Bio (QTTB) in Q2 2026, closing a stake of 84 shares — an estimated $539 sold.

Wells Fargo first reported a position in QTTB in Q2 2018 and held it in 30 quarters. The position peaked at $542K in Q4 2019. 72 funds tracked by Wall St. Rank hold QTTB as of Q2 2026.

  • Wells Fargo reported no remaining Q32 Bio position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 84 Q32 Bio shares in Q2 2026, an estimated $539.
  • Wells Fargo first reported a position in Q32 Bio in Q2 2018 and held it in 30 quarters.
  • Wells Fargo's Q32 Bio position peaked at $542K in Q4 2019.
  • 72 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.